Condition: Subdural Hematoma · Subdural Hematoma, Chronic · Sponsor: Aesculap AG
The aim of the study is to proof the effectiveness of Histoacryl® on preventing recurrence or progression of subdural hematoma after embolization of the middle meningeal artery.
This description comes directly from the study's public registry record.
Marta Soteras, Dr. · +34 935 8662 · studies@aesculap.de
Yumiko Okaniva, Dr. · +81 3814 · gen.jp@bbraun.jp
Always discuss trial participation with your own doctor first.
| Kobe City Medical Center General Hospital | Kobe, Chuo-ku, Japan | Not Yet Recruiting |
| Kokura Memorial Hospital | Fukuoka, Kitakyushu-city, Japan | Not Yet Recruiting |
| Ohara HealthCare Foundation Kurashiki Central Hospital | Okayama, Kurashiki, Japan | Not Yet Recruiting |
| Shimizu Hospital | Kyoto, Nishikyo-ku, Japan | Recruiting |
| National Hospital Organization Osaka National Hospital | Osaka-Fu, Osaka-shi, Japan | Not Yet Recruiting |
| Kyoto University Hospital | Kyoto, Sakyo-ku, Japan | Not Yet Recruiting |
| National Cerebral and Cardiovascular Center | Osaka, Suita, Japan | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07258069